Wall Street Zen Downgrades Metagenomi (NASDAQ:MGX) to Sell

Key Points

• Wall Street Zen downgraded Metagenomi (NASDAQ:MGX) from a "hold" to a "sell" and Weiss Ratings reiterated a "sell (D-)", though MarketBeat shows a consensus of "Moderate Buy" with a $10 target.
• Shares trade around $1.41 with a market cap of about $52.9M; the company reported a quarterly loss (EPS -$0.60) and missed revenue estimates ($3.91M), and analysts expect roughly -$2.46 EPS for the year.
• Several institutional investors have recently built or increased small stakes (BNP Paribas, Bank of America, Panagora, Quadrature, Dynamic Technology Lab), but overall positions remain modest in value.

Metagenomi (NASDAQ:MGX - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Metagenomi in a report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Metagenomi has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

Metagenomi Price Performance

NASDAQ MGX opened at $1.41 on Friday. The stock has a market capitalization of $52.86 million, a P/E ratio of -0.59 and a beta of 0.45. The business has a 50 day simple moving average of $1.56 and a 200 day simple moving average of $1.90. Metagenomi has a one year low of $1.23 and a one year high of $3.95.

Metagenomi (NASDAQ:MGX - Get Free Report) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.02). The business had revenue of $3.91 million during the quarter, compared to analyst estimates of $7.33 million. Metagenomi had a negative net margin of 348.54% and a negative return on equity of 47.14%. Equities analysts expect that Metagenomi will post -2.46 earnings per share for the current year.

Institutional Investors Weigh In On Metagenomi

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its holdings in shares of Metagenomi by 1,840.0% in the third quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company's stock valued at $36,000 after purchasing an additional 14,389 shares in the last quarter. Bank of America Corp DE grew its holdings in Metagenomi by 508.5% during the third quarter. Bank of America Corp DE now owns 18,766 shares of the company's stock worth $44,000 after buying an additional 15,682 shares in the last quarter. Panagora Asset Management Inc. bought a new stake in Metagenomi during the fourth quarter worth $53,000. Quadrature Capital Ltd purchased a new stake in Metagenomi in the 4th quarter valued at $55,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Metagenomi in the 3rd quarter valued at $64,000.

About Metagenomi

Metagenomi, Inc NASDAQ: MGX is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company's proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi's technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.